AngioDynamics (ANGO) Expected to Announce Quarterly Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) will likely be releasing its Q3 2026 results before the market opens on Thursday, April 2nd. Analysts expect AngioDynamics to post earnings of ($0.11) per share and revenue of $76.7670 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 8:00 AM ET.

AngioDynamics Trading Up 5.6%

AngioDynamics stock opened at $11.22 on Thursday. The firm has a market cap of $462.49 million, a P/E ratio of -16.75 and a beta of 0.48. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99. The firm has a 50-day moving average of $10.79 and a 200-day moving average of $11.54.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Zacks Research upgraded AngioDynamics from a “hold” rating to a “strong-buy” rating in a report on Friday, January 9th. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, AngioDynamics presently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

Hedge Funds Weigh In On AngioDynamics

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC lifted its position in AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the period. Kotler Kevin bought a new position in shares of AngioDynamics in the 4th quarter worth about $21,997,000. Armistice Capital LLC increased its stake in shares of AngioDynamics by 7.1% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the medical instruments supplier’s stock worth $18,274,000 after acquiring an additional 108,185 shares in the last quarter. Nuveen LLC lifted its position in AngioDynamics by 40.5% during the 4th quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after acquiring an additional 373,110 shares during the period. Finally, State Street Corp boosted its stake in AngioDynamics by 33.0% during the fourth quarter. State Street Corp now owns 1,272,735 shares of the medical instruments supplier’s stock worth $16,342,000 after acquiring an additional 315,844 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.